ライフサイエンスコーパス: cell activation

1 ol and hampers antigen presentation and MAIT cell activation.

2 LX2 HSCs prevented PFKFB3 overexpression and cell activation.

3 CD80 is a costimulatory receptor promoting T cell activation.

4 l fusion proteins that cause CD19-specific T-cell activation.

5 ir with HLA-B*57:01 binding and the CD8(+) T-cell activation.

6 the cytosolic Ca(2+) concentration rise upon cell activation.

7 ing to basement membrane remodeling and stem cell activation.

8 y to effectively recruit T cell help after B cell activation.

9 phorylation by Lck is an essential step in T cell activation.

10 of graft rejection relies on inhibition of T-cell activation.

11 r MR1 binding and inhibit MR1-dependent MAIT cell activation.

12 have long been appreciated to promote immune cell activation.

13 rosetting, but almost completely abrogated T-cell activation.

14 programme of signalling events leading to T cell activation.

15 lleles were associated with CD8 and/or CD4 T-cell activation.

16 feedback' receptors are induced upon immune cell activation.

17 ) are antigen-presenting cells controlling T cell activation.

18 ibitory coreceptor of the BCR and inhibits B cell activation.

19 f pyrimidine synthesis, reduces T-cell and B-cell activation.

20 ty reaction accompanied by enhanced CD4(+) T cell activation.

21 te being presented by HLA-E, resulting in NK cell activation.

22 ediators, which could further initiate glial cell activation.

23 CoV-2 infection may be compromising CD8(+) T cell activation.

24 er molecule and promotes IgE/Ag-induced mast cell activation.

25 escentic GN through antigen-specific T and B cell activation.

26 iffness lowers the agonist dose needed for T cell activation.

27 nals, a signal we refer to as signal 4 for T cell activation.

28 ng brain cellular inflammation and microglia cell activation.

29 decreased LRBA and CTLA-4 expression with T-cell activation.

30 ugmenting Th2-mediated inflammation and mast cell activation.

31 une function via inhibition of T cell and NK cell activation.

32 providing mechanical cues that costimulate T cell activation.

33 eractions with HLA-I and diminished CD8(+) T cell activation.

34 involved in the negative feedback of immune cell activation.

35 tion role in antibody expression following B cell activation.

36 horylation and increased antigen-dependent T cell activation.

37 ers are essential for robust inhibition of T cell activation.

38 s by the time-resolved data recorded after T cell activation.

39 g that gene deletion occurs independent of T cell activation.

40 delta T cells results in heightened CD4(+) T cell activation.

41 trol spatiotemporal gene expression during T cell activation.

42 changes of miRNA controlled networks upon T cell activation.

43 ovides insights into how LysRS works in mast cell activation.

44 present pathogen-derived peptides for CD4 T cell activation.

45 eractions are necessary to stimulate early T cell activation.

46 ory antigen-presenting cells that suppress T-cell activation.

47 orm on virus-like nanoparticles to enhance B-cell activation.

48 dendritic cells and MHCII-dependent CD4(+) T cell activation.

49 for responding to agonistic antigen-driven T cell activation.

50 oinhibitory molecules necessary for higher T cell activation.

51 mmunodeficiency with defects in T, B, and NK cell activation.

52 gulatory activity of FCRL4 on AgR-mediated B cell activation.

53 left, HLA-B*57:01 more potently inhibited NK cell activation.

54 molecules/cell to 1600 molecules/cell upon T-cell activation.

55 ined by epigenetic suppression of human mast cell activation.

56 capacity of DCs and tumor-specific CD8(+) T cell activation.

57 diminished serum IgE titers and reduced mast cell activation.

58 There was a modest decrease in CD8+ T-cell activation (-17.53% change for dipyridamole vs +13.

59 ited significantly higher levels of CD4(+) T cell activation, a difference that was lost over the fir

60 effect of IdeS on allo-antibody-mediated NK cell activation (Allo-CFC) and ADCC in vitro.

61 global stabilization of spliced mRNAs upon T cell activation, although the stability of intron-retain

62 indicates that metabolic programs regulate B cell activation and Ab responses.

63 s of AK2 and mitochondria, particularly in B-cell activation and antibody production.

64 acrophages are required for dental pulp stem cell activation and appropriate reparative dentine forma

65 lr1) deficiency significantly reduces immune cell activation and associated organ damage in the skin

66 eliorates the MPN phenotype, reduces stromal cell activation and BM fibrosis, and decreases the activ

67 ppresses HIV-1 transcription by inhibiting T cell activation and by modulating RNA splicing.

68 hromatin remodeling factor Brg1 impairs Treg cell activation and causes fatal autoimmunity in mice.

69 buting to HIV-1 pathogenesis by triggering T cell activation and cell death during viral spread.

70 ndings define AP-1 as the key link between T cell activation and chromatin remodeling.

71 clones (TCC) and characterize pathways of T cell activation and cross-reactivity with clozapine meta

72 of T-cell phenotype, function, pathways of T-cell activation and cross-reactivity with structurally r

73 (ii) blinatumomab induced B-cell-dependent T-cell activation and cytokine release to potentially trig

74 regulates multiple distinct checkpoints in T cell activation and differentiation and that these are m

75 olic reprogramming plays a central role in T cell activation and differentiation, and the inhibition

76 tion, hepatocytes with c-Jun activation show cell activation and DNA double-strand breaks.

77 dative damage, with consequent inhibition of cell activation and eventual cell death.

78 nses in PD, imaging evidence of inflammatory cell activation and evidence of immune dysregulation in

79 cal Trials Group study A5308 found reduced T-cell activation and exhaustion in human immunodeficiency

80 ation of expression of CD30 and markers of T-cell activation and exhaustion were performed along with

81 obulin mucin domain-3 (sTIM-3) (markers of T-cell activation and exhaustion), and sCD14 and sCD163 (m

82 MAIT cell priming in mice induces early MAIT cell activation and expansion after M. tuberculosis expo

83 iven by T cell signaling, promote effector T cell activation and expansion and Treg dysfunction.

84 AIT cell priming significantly enhanced MAIT cell activation and expansion early after M. tuberculosi

85 the mechanisms by which iron controls CD4 T cell activation and expansion remain poorly understood.

86 or the use of PET tracers that can monitor T-cell activation and expansion with high specificity.

87 ing is emerging as a critical regulator of T cell activation and function.

88 ry cytokines are sufficient for memory CD8 T cell activation and gain of effector functions, indicati

89 -renewal and multi-potency by affecting stem cell activation and glutaminolysis.

90 endogenous PD-L1 expression and restricted T cell activation and graft rejection.

91 -13, cytokines known for their roles in mast cell activation and growth-enhancing activity as well as

92 ncer, has recently been implicated in immune cell activation and growth.

93 ells, CD8+ T cells and NK cells, excessive T-cell activation and high expression of T-cell inhibitory

94 ical illness in COVID-19 with increased Th17 cell activation and IL-17 signaling that may lead to inc

95 ART in HIV controllers reduces T-cell activation and improves markers of immune exhaustio

96 we had shown ADPGK to play a major role in T-cell activation and induction of Warburg effect.

97 ecies and to limiting superantigen-induced T cell activation and interferon gamma (IFN-gamma) product

98 1H), a CD28/B7 family molecule, coinhibits T cell activation and is an attractive immunotherapeutic t

99 a hallmark of both early antigen-specific T cell activation and later chronic stimulation, suggestin

100 main in the T cell compartment reduced the T cell activation and maintained the expression of CD62L a

101 e expression of factors associated with mast cell activation and malaria-associated bacteremia in a r

102 otection was associated with suppressed mast cell activation and markedly reduced mast cell infiltrat

103 cytometry, combined with overall elevated T-cell activation and memory differentiation, suggesting h

104 CD8 T-cell activation and memory expansion are linked to HIV D

105 We describe distinct helper T cell activation and migration profiles along the colon a

106 n and remodeling via decreased smooth muscle cell activation and neutrophil transendothelial migratio

107 ent with monoclonal antibodies to enhance NK cell activation and NK cell-mediated killing.

108 ast, persisting viremia continued to drive T cell activation and PD-1 and CTLA-4 expression, and bloc

109 knocking down RIPK1 will reduce inflammatory cell activation and protect against the progression of a

110 diator of Aldo-induced valvular interstitial cell activation and proteoglycan secretion and CD (clust

111 control the signalling threshold for immune cell activation and receptors involved in the negative f

112 nge for cancer immunotherapy is sustaining T-cell activation and recruitment in immunosuppressive sol

113 gene diversification, coordination of immune cell activation and regulation of heterochromatin format

114 proliferation, inflammation, immunity, stem cell activation and regulation, extracellular matrix rem

115 te-based materials thereby accelerating stem cell activation and repair.

116 t MAIT cells repress group 2 innate lymphoid cell activation and restrict allergen-induced airway inf

117 T-cell activation and severity of acute pancreatitis did n

118 nts displayed hallmarks of extrafollicular B cell activation and shared B cell repertoire features pr

119 e skin, which resulted in exacerbated immune cell activation and skin pathology, mirroring that obser

120 g mice with anti-MerTK antibody stimulated T cell activation and synergized with anti-PD-1 or anti-PD

121 roducing T cells together with features of T-cell activation and systemic inflammation identified her

122 er, VAS2870 blocked the TLR9/RP105-induced B cell activation and thereby all Ig production.

123 highlight unresolved questions related to B cell activation and tolerance in vivo that may have impo

124 entry into the CR through HEVs, suppressed T cell activation, and altered T cell differentiation to s

125 and III responses, early CD4(+) and CD8(+) T cell activation, and counterregulation by the co-recepto

126 col for APC-ms synthesis and use for human T-cell activation, and discuss important considerations fo

127 ificantly reduced neutrophil infiltration, T-cell activation, and disease severity in mice.

128 ss rat paw inflammation, macrophage and mast cell activation, and histopathology induced by intraplan

129 hyperammonemia, evidence of hepatic stellate cell activation, and progressive fibrosis.

130 bility, IL-33 levels, type 2 innate lymphoid cell activation, and T(h)2 cell differentiation were fou

131 ):CD3 complex is required for USSN-induced T cell activation, and that direct receptor complex-partic

132 stinal fatty acid binding protein (IFABP), T-cell activation, and the inflammatory markers C-reactive

133 ( e.g., IgE) could engender potent effector cell activation, and unleash previously untapped immune

134 n the presence of co-stimulation-deficient T cell activation, anergy is a dominant hallmark that mand

135 -characterized biological effects on stromal cell activation, angiogenesis, and osteoclastogenesis.

136 phosphorylation and calcium flux following T cell activation are unaffected.

137 ase activity, and free Lck mediated higher T cell activation as compared to coreceptor-bound Lck.

138 a self-cleaving RNA and is cleaved during T-cell activation as well as thermal and endoplasmic retic

139 and adipose cells and how it promotes CD8 T cell activation, as well as epithelial repair.

140 rface expression and internalization after B cell activation, as well as promoting proliferation of p

141 A mast cell activation assay was used to determine whether an S

142 ing, confocal microscopy and a cognate CD4 T cell activation assay.

143 s pneumoniae vaccine were assessed in a MAIT cell activation assay.

144 Cell activation assays also showed that ACKR2-V41A cells

145 s, and these mapped to cytokine signalling/T-cell activation-associated pathways, with upstream drive

146 This approach enabled visualization of T-cell activation at early stages of disease, prior to ove

147 motryptic beta5i subunit of i-20S inhibits T cell activation, B cell proliferation, and dendritic cel

148 analyses of transcription factor and immune-cell activation based on transcriptome-wide empirical di

149 de B cell zone and also potent inducers of B cell activation both in vivo and in vitro.

150 pression of Malat1 is a hallmark of CD4(+) T cell activation, but its complete deletion results in mo

151 Together, these findings reveal that T cell activation by a bispecific T cell engager leads to

152 GF-beta influences the trajectory of early T-cell activation by altering PI3K activity and PtdIns lev

153 epsin L proteases and/or impairs host immune cell activation by blocking lysosomal cathepsin protease

154 To analyze human natural killer (NK) cell activation by both species, we performed ex vivo wh

155 However, the mechanisms of Ag transfer and B cell activation by DCs remain incompletely understood.

156 ghlight a novel extracellular mechanism of B cell activation by DCs.

157 T cell activation by dendritic cells (DCs) involves forces

158 ow that electrophilic compounds can impair T cell activation by distinct mechanisms involving the dir

159 is synapse is fully assembled and leads to T-cell activation by enabling interaction between the T-ce

160 ss II cell surface expression and impaired T cell activation by peptide-pulsed macrophages.

161 promoted the initiation of hepatic stellate cell activation by stimulating GPR55 and activation of A

162 MALT1 plays a central role in immune cell activation by transducing NF-kappaB signaling, and

163 blockade of such molecules facilitates the T cells activation by the DC vaccine.

164 nd CD86, suggesting that Ag processing and T cell activation capabilities are impaired.

165 A subgroup of patients had T cell activation characteristic of acute viral infection

166 The PROTACs showed enhanced inhibition of B cell activation compared to ibrutinib and exhibit potent

167 icolor flow cytometry during a variety of NK cell activation conditions was completed on primary huma

168 osis, and diminished pro-inflammatory immune cell activation; data that identifies and catalogues fun

169 to enhance mRNA stability, was involved in T cell activation-dependent mRNA stabilization.

170 Cellular metabolism regulates immune cell activation, differentiation and effector functions,

171 (2+) concentration, which is essential for T cell activation, differentiation and effector functions.

172 Loss of Yap in T cells results in enhanced T-cell activation, differentiation, and function, which tr

173 genes involved in antigen presentation and T cell activation during EAU.

174 o orthogonal challenges, including reduced T cell activation during viral or bacterial infection.

175 on, albeit not complete, on aberrant T and B cell activation following anti-CD86 blockade.

176 oexpression of MR1B with MR1A decreases MAIT cell activation following bacterial infection.

177 ile NKG7 also had a major impact on CD4(+) T cell activation following infection.

178 found differences in viral load and CD4(+) T cell activation from the earliest time points in men and

179 threonine sites within proteins regulating T cell activation, gene expression, and protein translatio

180 conventional immunosuppressants targeting T cell activation had limited effects on controlling rejec

181 rentiation and effector function following T cell activation has been extensively studied, little is

182 The "two-signal" model of B cell activation has long been invoked to explain alterna

183 ging constructs that can determine whether T-cell activation has occurred and could be used in drug d

184 However, ascertaining whether T-cell activation has occurred in vivo is difficult withou

185 Adamts18 is required for stem cell activation, has multiple binding partners in the ba

186 subsequently perturbed Ag presentation and T cell activation, higher TLR-mediated innate immune gene

187 eds light on the relationship between HLA, T-cell activation, immune control, and HIV pathogenesis.

188 line IFN production priming for inflammatory cell activation, immune response amplification, and deve

189 Our data suggest a role of B-cell activation in BCL development and a mediating role

190 NK cell activation in blood is mediated by humoral mediator

191 determine whether an S8mAb can inhibit mast cell activation in human lung tissue ex vivo.

192 hus, it clarifies the molecular picture of T cell activation in immune response.

193 e intracellular cytoskeleton is critical for cell activation in inflamed and fibrotic tissues; howeve

194 stion pathways in nonresponding tumors and T cell activation in responding tumors.

195 ceptor module (either CD8 or CD4) to drive T cell activation in response to pMHCI/II.

196 ns, we identified a mechanism whereby CD8+ T cell activation in response to programmed cell death 1 (

197 ratification according to patterns of immune cell activation in the kidney or identify disease featur

198 nhanced T-cell proliferation, and restored T-cell activation in the presence of VISTA-expressing canc

199 y macrophage skewing and increased dendritic cell activation in the tumor microenvironment, which wer

200 ssue-resident DCs, promoting disruption of T-cell activation in vitro.

201 he impact of these nanoscale parameters on B-cell activation in vitro.

202 However, unlike in men, higher CD4(+) T cell activation in women was not associated with higher

203 as downregulated at late time points after B cell activation, in a manner dependent on PI3K.

204 mast cell-mediated pathology and human mast cell activation, including the molecular mechanisms invo

205 t addition of missing self to DSA-induced NK cell activation increased endothelial damage.

206 n's HLA type may play a role in modulating T-cell activation independent of viral load and sheds ligh

207 ated cytokine production and do not induce T cell activation, independent of disease activity and the

208 nd 2-DG was efficacious in dampening mouse T cell activation-induced effector processes, relative to

209 ressing TAMs blocked cytotoxic T-cell and NK-cell activation, inhibiting their proliferation, cytokin

210 ening in MS is associated with innate immune cell activation inside and around WM lesions.

211 T cell activation is a cornerstone in manufacturing of T c

212 Immune cell activation is a strictly regulated and self-resolvi

213 Sustained B-cell activation is an important mechanism contributing t

214 -based therapies, and precise control over T cell activation is important in the development of the n

215 tabolism-the canonical pathways of intrinsic cell activation leading to changes in intracellular meta

216 However, mechanisms of immune cell activation leading to TLOs in COPD remain to be def

217 The activated macrophages caused stellate cell activation, leading to liver injury, by a mechanism

218 ction, IL-33 is elevated and promotes immune cell activation, leading to the development of asthma.

219 ere with epithelial cell alarmins, dendritic cell activation, macrophage function and T-cell responsi

220 Americans exhibited elevated expression of T-cell activation markers and higher plasma levels of IL-6

221 Aldo enhanced valvular interstitial cell activation markers and induced endothelial-mesenchy

222 alidate an approach using Mtb-specific CD4+T-cell activation markers in blood to discriminate PTB and

223 Cell activation markers in Mtb-specific CD4+T cells dist

224 ession is regulated independently of other T-cell activation markers.

225 scription factors that negatively regulate T-cell activation, may play a role in adaptive immune hypo

226 Furthermore, these early T cell activation metrics were predictive of GVHD onset 3-

227 okines/chemokines associated with help for B cell activation, migration and regulation compared to CD

228 mechanistic insights into Ag delivery and B cell activation modalities by DCs and a promising approa

229 rs NO production, which leads to endothelial cell activation, monocyte accumulation, foam cell format

230 ng antibody effector functions, including NK cell activation, monocyte phagocytosis, and complement a

231 upregulated gene pathways related to myeloid cell activation, myeloid cell migration, and phagocytosi

232 These interventions modulate Kupffer cell activation or macrophage polarization.

233 d cellular markers of monocyte activation, T-cell activation, oxidized lipids, and gut integrity.

234 Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19

235 rge intestine through the T cell-dependent B cell-activation pathway.

236 hed in BCCs and enriched immune response and cell activation pathways in SCCs.

237 Differentiation of natural killer (NK) cell activation pathways occurs along a continuum from r

238 increase in key enzymatic, inflammation and cell activation pathways.

239 in and provocation testing, and to explore T-cell activation pathways.

240 hown to substantially impact human primary T cell activation phenotypes.

241 yl chain of the AML strongly influences MAIT cell activation potency through dynamic compensatory int

242 cluding microRNAs (miRNAs), coordinate the T cell activation process.

243 factors include certain comorbidities, mast cell activation-related events affecting the cardiovascu

244 T-cell activation releases inositol 1,4,5-trisphosphate (I

245 y and rigidity of scaffold presentation on B-cell activation remain poorly understood.

246 llular signaling pathways that lead to CAR T cell activation remain unclear.

247 5-OP-RU affect presentation by MR1 and MAIT cell activation remains unclear.

248 and HLA-DR defining midterm and long-term T-cell activation, respectively, within skin-homing/cutane

249 , MAC may induce intracellular signaling and cell activation, responses implicated in a variety of au

250 TNIK-deficiency during T cell activation results in enhanced differentiation towa

251 ng affinity, CCL2 scavenging efficiency, and cell activation sensitivity.

252 omplex because of induction of the primary T cell activation signal.

253 tracellular adenosine levels and decreased T-cell activation significantly among persons with HIV-1 i

254 In addition, SASP-mediated endothelial cell activation stimulates the accumulation of CD8(+) T

255 For example, specific glycans regulate T-cell activation, structures, and functions of immunoglob

256 to the antigen presenting protein CD1b and T cell activation studies are used to confirm the antigeni

257 ncy of these compounds in inhibiting human T cell activation suggests that they may have therapeutic

258 stemic mastocytosis (SM) and monoclonal mast cell activation syndrome (MMAS), represent an increased

259 ID-19 in patients with mastocytosis and mast cell activation syndromes.

260 In the mast cell activation test, Ara h 2 induced significantly grea

261 ImmunoCAP inhibition experiments and mast cell activation tests in response to both Ara h 2 and Ar

262 contrast, female patients had more robust T cell activation than male patients during SARS-CoV-2 inf

263 ostimulator (ICOS) is a specific marker of T-cell activation that can be imaged by radiolabeling an a

264 limited AD show high levels of T(H)2/T(H)22 cell activation that is primarily localized to skin lesi

265 n E(2) biosythesis favors CD103(+) dendritic cell activation that primes a Tc1-polarized CD8(+) T cel

266 ter (CFSE) release assay and evaluated CAR-T cell activation through interferon gamma (IFN-gamma) pro

267 es that traffic to lymph nodes and trigger B cell activation through multivalent and oriented antigen

268 (QVOAs) in which latency is reversed with T cell activation to allow viral outgrowth.

269 editing approaches beyond models of robust T cell activation to encompass both naive T cell homeostas

270 nocytosis that increases in magnitude upon T cell activation to support T cell growth even under amin

271 n of missing self amplifies DSA-dependent NK cell activation to worsen chronic AMR.

272 dual maps of white matter (WM) innate immune cell activation using (18)F-DPA-714 translocator protein

273 ne levels; primary endpoints were cervical T cell activation, vaginal microbial diversity and cytokin

274 evels and lower peripheral blood mononuclear cell activation versus both groups.

275 pecific inhibitory receptors that prevent NK cell activation via cytoplasmic ITIM.

276 associated protein 4 (CTLA-4), which limit T cell activation via synergistic mechanisms.

277 how protein aggregates could induce DC and T cell activation via the FcgammaRIIa-Syk signaling pathwa

278 we investigated mechanisms for suppressing T-cell activation via the inhibitory receptor leukocyte-as

279 V-domain Ig suppressor of T-cell activation (VISTA) is an immune checkpoint that aff

280 V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA) is an immune checkpoint that mai

281 noglobulin domain-containing suppressor of T cell activation (VISTA) is expressed on naive T cells.

282 During ART, inflammation and CD4(+) T cell activation wane, resulting in reduced cell turnover

283 onocytogenes (L.m) infection, and whether NK cell activation was affected.

284 Systemic mast cell activation was determined by serum Mcpt1 ELISA in r

285 B-cell activation was followed by expansion of circulating

286 and anaphylactogenic potency but retained T-cell activation was generated.

287 Cell activation was significantly higher in NHS ester-co

288 Following T-cell activation, WASP is degraded, leading to cytoskelet

289 s, cellular cytotoxicity, and natural killer cell activation were assessed.

290 trophilia and higher levels of CD4 and CD8 T-cell activation were found in CDC patients as well as in

291 We show that IFN-I production and T cell activation were performed by the same pDC, but thes

292 Inhibiting IRE1alpha blocked stellate cell activation, which then decreased proliferation and

293 -9, and IL-13 that maintain and enhance mast cell activation while disrupting the protease/antiprotea

294 ring sequential waves of polyclonal CD4(+) T cell activation while simultaneously enhancing virus pro

295 at eight time points during memory CD4(+) T cell activation with high-depth RNA-seq in healthy indiv

296 bial translocation (LPS, IFABP, sCD14, and T-cell activation), with decreased EndoCAb IgM.

297 analyses also uncovered multifaceted immune cell activation within brain malignancies entailing conv

298 that is characterized by dominant T-helper 2 cell activation without adequate counter-regulation by T

299 Noninvasive strategies detecting T-cell activation would allow for early diagnosis and poss

300 ecretion of costimulatory cytokines during T-cell activation, yet data to support this notion in vivo